NEW YORK, July 11, 2026, 06:44 EDT
Biotech names Vertex Pharmaceuticals NASDAQ:VRTX and Ionis Pharmaceuticals NASDAQ:IONS slumped after two big setbacks, wiping out about $14.8 billion in market value over the five sessions through Friday. That’s going by Friday’s share counts and using July 2 and July 10 close, even as a takeover target in the sector almost doubled.
On the flip side, Crinetics Pharmaceuticals NASDAQ:CRNX, BridgeBio Pharma NASDAQ:BBIO and Vera Therapeutics NASDAQ:VERA together added around $6.1 billion. Investing.com The SPDR S&P Biotech ETF (NYSEARCA:XBI) dropped 0.9%, but the SPDR S&P 500 ETF NYSEARCA:SPY rose 1.4%. Money moved inside biotech in targeted ways, hitting approved drugs, M&A, and trial risk harder than usual.
| Stock | Week’s trigger | July 2 close | July 10 close | Weekly move | Approx. value change |
|---|---|---|---|---|---|
| Vertex NASDAQ:VRTX | Announced $10B deal for Crinetics | $528.04 | $485.39 | -8.1% | -$10.9 billion |
| Crinetics NASDAQ:CRNX | Got $85/share buyout offer | $42.23 | $83.58 | +97.9% | +$4.3 billion |
| Ionis NASDAQ:IONS | Wainua study failed to meet goal | $81.80 | $58.25 | -28.8% | -$3.9 billion |
| BridgeBio NASDAQ:BBIO | ATTR-CM data from competitor | $77.19 | $85.89 | +11.3% | +$1.7 billion |
| Vera NASDAQ:VERA | Trutakna gets FDA nod | $41.20 | $42.00 | +1.9% | +$0.1 billion |
| XBI (NYSEARCA:XBI) | Biotech sector gauge | $160.46 | $159.03 | -0.9% | — |
| SPY NYSEARCA:SPY | S&P 500 tracker | $744.78 | $754.95 | +1.4% | — |
Estimated value changes are based on Friday’s market prices, with the week’s share count kept the same.
Vertex is buying Crinetics at $85 a share, putting the target’s value near $10 billion and offering a 102% premium over Monday’s close. With the deal, Vertex gets Palsonify, an approved treatment for acromegaly, and late-stage candidate atumelnant. The companies project peak yearly sales above $5 billion. Scotiabank’s Louise Chen said this makes endocrinology a fifth business line for Vertex. CEO Reshma Kewalramani said the company’s capital allocation plan stays the same.
The second miss was from Wainua, an ATTR-CM drug that AstraZeneca NASDAQ:AZN and Ionis are developing. Wainua failed on its main goal—cutting cardiovascular deaths and repeat heart issues. Analysts had hoped for a $2 billion peak sales number. BofA’s Sachin Jain called the data “comes as a surprise.” Reuters
The trial design sheds light on why stocks didn’t trade together. AstraZeneca research head Sharon Barr said the trial tested Wainua “on top of today’s standard of care.” At baseline, 57% of patients were already on a transthyretin stabilizer—drugs that keep the protein from breaking up—and another 24% started one during the trial. Wainua didn’t move the needle in the baseline-stabilizer group but showed a suggestive result, not conclusive, when used alone. BridgeBio, which makes the stabilizer Attruby, kept an 11.3% weekly gain. Alnylam Pharmaceuticals NASDAQ:ALNY, the company behind Amvuttra, a gene-silencer, dropped from a 17% intraday pop on Thursday to finish the week down 4.5%. The divergence points to investors seeing this as a positive for stabilizers rather than for every competitor. astrazeneca.com
Vera’s win came with less drama. The FDA gave accelerated approval to Trutakna for IgA nephropathy, a type of kidney disease tied to immune deposits. Accelerated approvals let drugs through based on early markers, in this case lower urine protein, before long-term outcomes. Trutakna dropped urine protein 42% at 36 weeks compared to placebo. Chief Commercial Officer Matt Skelton listed the wholesale price at $425,000 per year. Shares ended the week up just 1.9%.
Apnimed filed for a U.S. IPO on Friday, planning to list on Nasdaq as APMD. The move comes as biotech IPOs slump to their lowest in over a decade in 2025, but the filing suggests the window may be starting to open, if slowly. Apnimed’s main drug, AD109, has a marketing application pending, with an FDA decision possibly coming in the first quarter of 2027.
But none of these trades is locked in. Vertex still has to close, integrate, and launch its new big buy. Ionis could bounce back if upcoming Wainua subgroup results suggest it can go it alone. Vera needs to nail down insurance coverage at a steep price, then show it can protect kidneys. On the downside: Crinetics’s rollout could drag, Wainua might not pan out in heart disease, and pushback over Trutakna’s price is possible.
There are two confirmed tests set for next week, both at different stages in the development process.
| Date | Company | Confirmed catalyst | Main investor question |
|---|---|---|---|
| Monday, July 13 | Q32 Bio NASDAQ:QTTB | Q32 Bio releases 36-week data for bempikibart in alopecia areata at 8:00 a.m. EDT | Can the clinical results stay strong after 36 weeks? |
| Friday, July 17 | Celcuity NASDAQ:CELC | FDA set to rule on gedatolisib for a type of advanced breast cancer | Will priority review lead straight to approval and a launch? |
Q32’s upcoming data will be a test of clinical durability, while Celcuity’s move gives a more straightforward regulatory event. This week showed that biotech demand hasn’t gone away, but the broad rebound has split into stock-picking. Weak evidence is getting punished at full cost.
